RxDoctor Payments Data

Alan Rosen, MD

Cardiovascular Disease · Framingham, MANPI 1841464757

Payments from drug & device makers

$349in general payments, 2019–2025

Across 12 payments — averaging $29.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$105
  • Boston Scientific$69
  • Lantheus Medical Imaging, Inc.$59
  • Amgen$52
  • Boehringer Ingelheim$26
  • Johnson & Johnson$21
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$349 in reported general payments places this provider in the 30th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$299,251
Medicare patients
1,030
Services billed
2,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban365$452,168
EntrestoSacubitril/Valsartan71$121,949
JardianceEmpagliflozin53$71,389
XareltoRivaroxaban51$67,281
Repatha SureclickEvolocumab57$50,169
FarxigaDapagliflozin Propanediol24$27,887
Praluent PenAlirocumab19$20,437
VascepaIcosapent Ethyl31$18,262
Icosapent Ethyl43$18,165
Metoprolol Succinate547$11,743
Atorvastatin Calcium578$10,024
Ezetimibe198$6,744
Rosuvastatin Calcium210$6,361
Ranolazine ErRanolazine36$5,406
Losartan Potassium272$3,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$452,168365 claims
Boehringer IngelheimJardiance$26$71,38953 claims
Johnson & JohnsonXarelto$21$67,28151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →